At RESCEU Project we envision a world without #RSV. Future vaccines hold the key to prevent children, elder adults, and risk groups from getting sick. We join #WHO on #WorldImmunizationWeek to assert that #vaccineswork and bring us closer. who.int/campaigns/worl…. @IMI_JU

Temporal Variations in Respiratory Syncytial Virus Epidemics, by Virus Subtype, 4 Countries pubmed.ncbi.nlm.nih.gov/33900190/?utm_…

Proud to lead RESCEU Project - a highly productive group of top flight investigators committed to creating an evidence base to stop #RSV.

Learning more with @rebaker64 from Princeton University about the impact of #COVID19 on #RSV dynamics and what to expect in months and years to come. #Keynote #RESCEU_GAM5

RESCEU Project 5th General Assembly Meeting is now over! 👋👋 90+ participants have got together for the past 2 days to share and debate advances made in #RSV research by this @IMI_JU project & set next steps. 🔬🩺🎯 🫂 See you at our next and final GAM! Hopefully face to face.🙏

The RSV epidemic is nearly over in Belgium. Couple of lessons: late epidemic in 2021, small epidemic compared to previous years, length quite similar to previous winters, Easter school holidays appear to have disrupted 2021 epidemic and most cases in children aged 0-4 (as usual)

Proud to be part of PROMISE Project to further expand our knowledge of respiratory syncytial virus #RSV and help pave the way for novel RSV immunizations and therapeutic approaches aimed at addressing a high global unmet need.

Really excited to be working with leading #RSV scientists in Europe to pave the way for introduction of novel vaccines and therapeutics against RSV. PROMISE Project builds on the successes of RESCEU Project over past 5 years. John Paget, PhD Hanna Nohynek Andrew Pollard Peter Openshaw Louis Bont

Respiratory syncytial virus is a contagious, usually mild virus that can send infants to doctors & hospitals in the winter. As COVID-19 restrictions eased, infections increased. This year’s #RSV activity demands attention. Learn more: sanofi.com/en/about-us/ou…

Here it is the RSV revolution! Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants | NEJM nejm.org/doi/full/10.10…

Intense RSV epidemic is forecasted in South Africa in early 2022: 'Our results suggest that hospital system readiness should be prepared for an intense RSV season in early 2022.' medrxiv.org/content/10.110…

2022 is off to a great start: continuation of patient recruitment, development of #researchmodels, article publication and on time reporting! Read work package updates here 👉 bit.ly/3EfTgGR and stay tuned for more to come!  Innovative Health Initiative EFPIA

📢Our brand-new website is now live! Check it out ⏩imi-promise.eu 🧐Discover the PROMISE Project project and learn more about our vision to pave the way to #RSV disease prevention, treatment, and immunisation. Innovative Health Initiative

#RSV is the single most important respiratory virus that causes substantial morbidity and mortality in <6 month infants worldwide. Our results 👇show that 80% of RSV deaths occur outside hospital. The RSV immunisation landscape looks promising - we may have licensed products

#RSV on rebound in many countries. Countries should prepare for RSV epidemic this autumn / winter - hospitals likely to be under severe pressure. ⁦Louis Bont ⁦Federico Martinón-Torres⁩ ⁦Shabir Madhi⁩. Cold virus killed 100,000 children globally in 2019 bbc.co.uk/news/health-61…

Very proud of such achievement. Juge congratulations to all partners who contribuâtes to these two wonderful partnerdhips!

A varicella–zoster virus subunit vaccine w AS01B adjuvant has efficacy of >96% in preventing herpes zoster. nej.md/1J6nB75

Major concern: 50% of typhoid isolates became drug resistant prior to recent typhoid outbreaks in #Malawi, shares N Feasy #TyphoidNTS

Vaccination benefit!!! x.com/lemondefr/stat…

Very good news for fight against cholera! news-medical.net/news/20150710/…